News | News By Subject | News by Disease News By Date | Search News

Diabetic neuropathy News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
BioDelivery Sciences International (BDSI) Clonidine Topical Gel Fails Phase III, Shares Plunge     3/31/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
FDA Grants Priority Review For Genentech (RHHBY)’s Lucentis In Diabetic Retinopathy     10/9/2014
Regeneron Pharmaceuticals, Inc. (REGN) Wins Breakthrough Therapy Designation From FDA For EYLEA     9/18/2014
Quigley Corporation (QGLY) Announces Final Results of Quigley Pharma Inc. (QGLY)'s Phase IIb Study     7/22/2009
Sangamo BioSciences, Inc. (SGMO) Drug SB-509 Fails Midstage Study     11/11/2008
Pfizer Inc. (PFE) (JOBS) Cancels Phase III of Glaucoma Drug Research in Asia     8/25/2008
Sangamo BioSciences, Inc. (SGMO) Announces Completion of Accrual and Expansion Plans for SB-509-701 Phase 2 Clinical Trial for Treatment of Moderate to Severe Diabetic Neuropathy     6/6/2008
Exelixis, Inc. (EXEL) Says GlaxoSmithKline (GSK) Does Not Option XL784 for Further Development     1/21/2008
Keryx Biopharmaceuticals (KERX): Panel Says Drug Candidate Doesn't Raise Safety Concerns     12/6/2007
Pfizer Inc. (PFE)'s (Jobs) Lyrica Receives FDA Approval for Fibromyalgia Based on Expedited Review     6/22/2007
AVANIR Pharmaceuticals (AVNR) Shares Rise; Zenvia Shows Positive Phase 3 Results for Diabetes-Related Nerve Pain     6/8/2007
AVANIR Pharmaceuticals (AVNR) Says Drug Shows Positive Results; Shares Soar     4/18/2007

News from Around the Web

Press Releases
BioNevia And Neuromax Announce Completion Of Enrollment In Phase IIb Clinical Trial Of BNV-222     5/16/2016
Theravance (THRX) Announces First Subject Dosed In Phase 1 Clinical Trial Of TD-0714, An Inhibitor Of Neprilysin (NEP)     12/9/2015
Concert Pharmaceuticals, Inc. (CNCE) Reports Third Quarter 2015 Financial Results And Provides Company Update     11/5/2015
NephroGenex (NRX) To Host Conference Call And Webcast On Third Quarter 2015 Financial Results On Thursday, November 12, 2015     11/4/2015
NephroGenex (NRX) Reports Second Quarter 2015 Financial Results     8/13/2015
NephroGenex (NRX) To Host Conference Call And Webcast On Second Quarter 2015 Financial Results On Thursday, August 13, 2015     8/7/2015
Hydra Biosciences, Inc. Appoints Leading Pulmonary Experts To Newly Created Medical Advisory Board     8/5/2015
Vital Art And Science Announces A New US Patent For Its Mvt Service For Age Related Macular Degeneration And Diabetic Retinopathy Patients     7/8/2015
Positive Results From ChemoCentryx, Inc. (CCXI) Phase II Diabetic Nephropathy Trial With Chemokine Receptor CCR2 Inhibitor CCX140 Highlighted At The 52nd ERA-EDTA Congress     5/29/2015
Positive Clinical Data From ChemoCentryx, Inc. (CCXI) Phase II Trial In Diabetic Nephropathy To Be Presented At The 52nd Annual ERA-EDTA Congress     5/26/2015
Hydra Biosciences, Inc. Receives Approval From Health Canada To Begin Phase 1 Trial For HX-100     4/14/2015
ChemoCentryx, Inc. (CCXI) Announces Positive Results In Phase 2 Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140     12/12/2014
ChemoCentryx, Inc. (CCXI)To Host Conference Call On Friday, December 12, 2014 To Discuss Top-Line Phase 2 Results In Patients With Diabetic Nephropathy With CCX140, An Orally Administered CCR2 Inhibitor     12/12/2014
BioDelivery Sciences International (BDSI) Announces Completion Of Randomization In Phase 3 Trial Of Clonidine Topical Gel For The Treatment Of Painful Diabetic Neuropathy     12/8/2014
GenKyoTex S.A. Completes Enrollment Into Phase 2 Trial Of NOX1&4 Inhibitor GKT137831 In Diabetic Nephropathy     11/13/2014

//-->